Citations (100)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Dimple Butani, Nidhi Gupta, Gaurav Jyani, Pankaj Bahuguna, Rakesh Kapoor & Shankar Prinja. (2021) Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India. Breast Cancer: Targets and Therapy 13, pages 625-640.
Read now
Read now
Karinna Saxby, Carolyn Nickson, G Bruce Mann, Allan Park, Hannah Bromley, Louiza Velentzis, Pietro Procopio, Karen Canfell & Dennis Petrie. (2021) Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 847-857.
Read now
Read now
Seon-Ha Kim, Min-Woo Jo, Minsu Ock, Hyeon-Jeong Lee & Jong-Won Lee. (2017) Estimation of health state utilities in breast cancer. Patient Preference and Adherence 11, pages 531-536.
Read now
Read now
Noman Paracha, Per-Olof Thuresson, Santiago G. Moreno & Katherine S. MacGilchrist. (2016) Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 16:5, pages 549-559.
Read now
Read now
J. U. Blohmer, M. Rezai, S. Kümmel, T. Kühn, M. Warm, K. Friedrichs, A. Benkow, W. J. Valentine & W. Eiermann. (2013) Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. Journal of Medical Economics 16:1, pages 30-40.
Read now
Read now
Christos Markopoulos. (2013) Overview of the use of Oncotype DX® as an additional treatment decision tool in early breast cancer. Expert Review of Anticancer Therapy 13:2, pages 179-194.
Read now
Read now
Franz Porzsolt, Igor Polianski, Arno Görgen & Martin Eisemann. (2011) Safety and Security: The Valences of Values. Journal of Applied Security Research 6:4, pages 483-490.
Read now
Read now
Articles from other publishers (93)
Anthony J. Hatswell. (2023) Incorporating Prior Beliefs Into Meta-Analyses of Health-State Utility Values Using the Bayesian Power Prior. Value in Health 26:9, pages 1389-1397.
Crossref
Crossref
Olfat Ahmad, Christian Sutter, Steffen Hirsch, Stefan M. Pfister & Christian P. Schaaf. (2023) BRCA1/2 potential founder variants in the Jordanian population: an opportunity for a customized screening panel. Hereditary Cancer in Clinical Practice 21:1.
Crossref
Crossref
Gregory F. Guzauskas, Shawn Garbett, Zilu ZhouJonathan S. SchildcroutJohn A. Graves, Marc S. Williams, Jing Hao, Laney K. Jones, Scott J. SpencerShangqing JiangDavid L. VeenstraJosh F. Peterson. (2023) Population Genomic Screening for Three Common Hereditary Conditions. Annals of Internal Medicine 176:5, pages 585-595.
Crossref
Crossref
Yubo Wang, Sean P. Gavan, Douglas Steinke, Kwok-Leung Cheung & Li-Chia Chen. (2022) The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression. Health and Quality of Life Outcomes 20:1.
Crossref
Crossref
Florian Schwarz, Habibollah Arefian, Michael Hartmann & Ingo Runnebaum. (2022) Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. PLOS ONE 17:12, pages e0278460.
Crossref
Crossref
Ifigeneia Mavranezouli, Jo Varley-Campbell, Sarah Stockton, Jennifer Francis, Clare Macdonald, Sunita Sharma, Peter Fleming, Elizabeth Punter, Charlotte Barry, Maija Kallioinen, Nina Khazaezadeh & David Jewell. (2022) The cost-effectiveness of antenatal and postnatal education and support interventions for women aimed at promoting breastfeeding in the UK. BMC Public Health 22:1.
Crossref
Crossref
Rana El Haidari, Amelie Anota, Tienhan S. Dabakuyo-Yonli, Francis Guillemin, Thierry Conroy, Michel Velten, Damien Jolly, Sylvain Causeret, Jean Cuisenier, Olivier Graesslin, Linda Abou Abbas & Virginie Nerich. (2022) Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments. Quality of Life Research 31:10, pages 3077-3085.
Crossref
Crossref
Stephanie B. Wheeler, Jason Rotter, Anagha Gogate, Katherine E. Reeder-Hayes, Sarah W. Drier, Donatus U. Ekwueme, Temeika L. Fairley, Gabrielle B. Rocque & Justin G. Trogdon. (2022) Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer. Journal of Clinical Oncology.
Crossref
Crossref
Marina Lourenção, Julia Simões Correa Galendi, Henrique de Campos Reis Galvão, Augusto Perazzolo Antoniazzi, Rebeca Silveira Grasel, André Lopes Carvalho, Edmundo Carvalho Mauad, Jorge Henrique Caldeira de Oliveira, Rui Manuel Reis, Olena Mandrik & Edenir Inêz Palmero. (2022) Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country. Frontiers in Oncology 12.
Crossref
Crossref
Manraj N. Kaur, Jiajun Yan, Anne F. Klassen, Justin P. David, Dilshan Pieris, Manraj Sharma, Louise Bordeleau & Feng Xie. (2022) A Systematic Literature Review of Health Utility Values in Breast Cancer. Medical Decision Making 42:5, pages 704-719.
Crossref
Crossref
Yuan Zhang, Shelly-Anne Li, Juan Jose Yepes-Nuñez, Rebecca L. Morgan, Hector Pardo-Hernandez, Pablo Alonso Coello, Melody Ren, Reza D. Mirza, Gordon H. Guyatt & Holger J. Schünemann. (2022) GRADE summary of findings tables enhanced understanding of values and preferences evidence. Journal of Clinical Epidemiology 147, pages 60-68.
Crossref
Crossref
Claudine Bommer, Judith Lupatsch, Nicole Bürki & Matthias Schwenkglenks. (2021) Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland. The European Journal of Health Economics 23:5, pages 807-821.
Crossref
Crossref
Yubo Wang, Sean P. Gavan, Douglas Steinke, Kwok-Leung Cheung & Li-Chia Chen. (2022) Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer. Cost Effectiveness and Resource Allocation 20:1.
Crossref
Crossref
Christine M. Veenstra, Thomas M. Braun, Paul H. Abrahamse, Daniela Wittmann & Sarah T. Hawley. (2022) Employment outcomes in family supporters of patients with early stage breast cancer and their association with patients’ health‐related quality of life and financial burden. Cancer Medicine 11:5, pages 1324-1335.
Crossref
Crossref
Mingyu Jiang, Yue Ma, Minghui Li, Rui Meng, Aixia Ma & Pingyu Chen. (2021) A comparison of self-reported and proxy-reported health utilities in children: a systematic review and meta-analysis. Health and Quality of Life Outcomes 19:1.
Crossref
Crossref
Tsuguo Iwatani, Eisuke Inoue & Koichiro Tsugawa. (2021) Validation of the predictive accuracy of health-state utility values based on the Lloyd model for metastatic or recurrent breast cancer in Japan. BMJ Open 11:12, pages e046273.
Crossref
Crossref
Tsuguo Iwatani, Shinichi Noto & Koichiro Tsugawa. (2021) Changes in Health State Utility Values in Japanese Patients with End-Stage Breast Cancer. Current Oncology 28:5, pages 4203-4212.
Crossref
Crossref
Julia Simões Corrêa Galendi, Vera Vennedey, Hannah Kentenich, Stephanie Stock & Dirk Müller. (2021) Data on Utility in Cost–Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer. Cancers 13:19, pages 4879.
Crossref
Crossref
Rebecca Addo, Marion Haas & Stephen Goodall. (2021) The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor–Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women. Value in Health Regional Issues 25, pages 196-205.
Crossref
Crossref
Shah Alam Khan, Karla Vanessa Hernandez‐Villafuerte, Muchandifunga Trust Muchadeyi & Michael Schlander. (2021) Cost‐effectiveness of risk‐based breast cancer screening: A systematic review. International Journal of Cancer 149:4, pages 790-810.
Crossref
Crossref
Michael J. Zoratti, A. Simon Pickard, Peep F. M. Stalmeier, Daniel Ollendorf, Andrew Lloyd, Kelvin K W Chan, Don Husereau, John E. Brazier, Murray Krahn, Mitchell Levine, Lehana Thabane & Feng Xie. (2021) Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. The European Journal of Health Economics 22:5, pages 723-733.
Crossref
Crossref
Nathaniel Hendrix, David D. Kim, Krishna S. Patel & Beth Devine. (2021) Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses. Medical Decision Making 41:3, pages 366-372.
Crossref
Crossref
J A Murphy, D Myers, P Trueman & R Searle. (2021) Cost-effectiveness of single-use negative-pressure therapy compared with standard care for prevention of reconstruction failure in prepectoral breast reconstruction. BJS Open 5:2.
Crossref
Crossref
Julia Simoes Correa-Galendi, Maria del Pilar Estevez Diz, Stephanie Stock & Dirk Müller. (2020) Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer. Applied Health Economics and Health Policy 19:1, pages 97-109.
Crossref
Crossref
Jiryoun Gong, Juhee Han, Donghwan Lee & Seungjin Bae. (2020) A Meta-Regression Analysis of Utility Weights for Breast Cancer: The Power of Patients’ Experience. International Journal of Environmental Research and Public Health 17:24, pages 9412.
Crossref
Crossref
Natalia Kunst, Shi-Yi Wang, Annette Hood, Sarah S. Mougalian, Michael P. DiGiovanna, Kerin Adelson & Lajos Pusztai. (2020)
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With
ERBB2
(
HER2
)–Positive Breast Cancer
. JAMA Network Open 3:11, pages e2027074.
Crossref
Crossref
Gregory F. Guzauskas, Shawn Garbett, Zilu Zhou, Scott J. Spencer, Hadley S. Smith, Jing Hao, Dina Hassen, Susan R. Snyder, John A. Graves, Josh F. Peterson, Marc S. Williams & David L. Veenstra. (2020) Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States. JAMA Network Open 3:10, pages e2022874.
Crossref
Crossref
H. Amarens Geuzinge, Inge-Marie Obdeijn, Emiel J. T. Rutgers, Sepideh Saadatmand, Ritse M. Mann, Jan C. Oosterwijk, Rob A. E. M. Tollenaar, Diderick B. W. de Roy van Zuidewijn, Marc B. I. Lobbes, Martijne van ‘t Riet, Maartje J. Hooning, Margreet G. E. M. Ausems, Claudette E. Loo, Jelle Wesseling, Ernest J. T. Luiten, Harmien M. Zonderland, Cees Verhoef, Eveline A. M. Heijnsdijk, Madeleine M. A. Tilanus-Linthorst & Harry J. de Koning. (2020) Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. JAMA Oncology 6:9, pages 1381.
Crossref
Crossref
Savvas S. Ioannou, Yiola Marcou, Eleni Kakouri & Michael A. Talias. (2020) Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective. International Journal of Environmental Research and Public Health 17:12, pages 4339.
Crossref
Crossref
Popy Yuniar, Suzanne Robinson, Rachael Moorin & Richard Norman. (2020) Economic Evaluation of Breast Cancer Early Detection Strategies in Asia: A Systematic Review. Value in Health Regional Issues 21, pages 252-263.
Crossref
Crossref
Qiuji Wu, Xinyuan Wang, Mengxi Zhang, Weiting Liao, Feng Wang & Qiu Li. (2020) Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer. Oncology Research and Treatment 43:4, pages 153-159.
Crossref
Crossref
Jyoti Khadka, Joseph Kwon, Stavros Petrou, Emily Lancsar & Julie Ratcliffe. (2019) Mind the (inter-rater) gap. An investigation of self-reported versus proxy-reported assessments in the derivation of childhood utility values for economic evaluation: A systematic review. Social Science & Medicine 240, pages 112543.
Crossref
Crossref
Carlota Moya-Alarcón, Almudena González-Domínguez, Susana Simon, Inés Pérez-Román, Antonio González-Martín, Eloisa Bayo-Lozano & Ana Beatriz Sánchez-Heras. (2019) Cost–utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain. Clinical and Translational Oncology 21:8, pages 1076-1084.
Crossref
Crossref
Lin Li, J. L. (Hans) Severens & Olena Mandrik. (2019) Disutility associated with cancer screening programs: A systematic review. PLOS ONE 14:7, pages e0220148.
Crossref
Crossref
Joseph Kwon, Sung Wook Kim, Wendy J. Ungar, Kate Tsiplova, Jason Madan & Stavros Petrou. (2019) Patterns, trends and methodological associations in the measurement and valuation of childhood health utilities. Quality of Life Research 28:7, pages 1705-1724.
Crossref
Crossref
Dirk Müller, Marion Danner, Rita Schmutzler, Christoph Engel, Kirsten Wassermann, Björn Stollenwerk, Stephanie Stock & Kerstin Rhiem. (2019) Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer. The European Journal of Health Economics 20:5, pages 739-750.
Crossref
Crossref
Sue Harnan, Paul Tappenden, Katy Cooper, John Stevens, Alice Bessey, Rachid Rafia, Sue Ward, Ruth Wong, Robert C Stein & Janet Brown. (2019) Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment 23:30, pages 1-328.
Crossref
Crossref
Feng Xie, Michael Zoratti, Kelvin Chan, Don Husereau, Murray Krahn, Oren Levine, Tammy Clifford, Holger Schunemann & Gordon Guyatt. (2019) Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). Medical Decision Making 39:4, pages 371-379.
Crossref
Crossref
Hannah L. Bromley, Dennis Petrie, G.Bruce Mann, Carolyn Nickson, Daniel Rea & Tracy E. Roberts. (2019) Valuing the health states associated with breast cancer screening programmes: A systematic review of economic measures. Social Science & Medicine 228, pages 142-154.
Crossref
Crossref
Shunping Li, Min Wang, Liu Liu & Gang Chen. (2019) Which approach is better in eliciting health state utilities from breast cancer patients? Evidence from mainland China. European Journal of Cancer Care 28:2, pages e12965.
Crossref
Crossref
J. Jaime Caro, John E. Brazier, Jonathan Karnon, Peter Kolominsky-Rabas, Alistair J. McGuire, Erik Nord & Michael Schlander. (2018) Determining Value in Health Technology Assessment: Stay the Course or Tack Away?. PharmacoEconomics 37:3, pages 293-299.
Crossref
Crossref
Nasuh C. Büyükkaramikli, Saskia de Groot, Rob Riemsma, Debra Fayter, Nigel Armstrong, Piet Portegijs, Steven Duffy, Jos Kleijnen & Maiwenn J. Al. (2018) Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 37:2, pages 141-153.
Crossref
Crossref
Lars Asphaug & Hans Olav Melberg. (2019) The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway. MDM Policy & Practice 4:1, pages 238146831882110.
Crossref
Crossref
Javier Cortes, José Pérez-García, Scott Whiting, Yin Wan, Caitlyn Solem, Ming-Hui Tai, Sandra Margunato-Debay, Amy Ko, Abderrahim Fandi & Marc Botteman. (2018) Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis. Clinical Breast Cancer 18:5, pages e919-e926.
Crossref
Crossref
Stavros Petrou, Joseph Kwon & Jason Madan. (2018) A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values. PharmacoEconomics 36:9, pages 1043-1061.
Crossref
Crossref
Verin Lertjanyakun, Nathorn Chaiyakunapruk, Susumu Kunisawa & Yuichi Imanaka. (2018) Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor–positive and Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in Japan. PharmacoEconomics 36:9, pages 1113-1124.
Crossref
Crossref
Susan K. Parsons, Michael J. Kelly, Joshua T. Cohen, Sharon M. Castellino, Tara O. Henderson, Kara M. Kelly, Frank G. Keller, Tobi J. Henzer, Anita J. Kumar, Peter Johnson, Ralph M. Meyer, John Radford, John Raemaekers, David C. Hodgson & Andrew M. Evens. (2018) Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. British Journal of Haematology 182:2, pages 212-221.
Crossref
Crossref
Micah Rose, Stephen Rice & Dawn Craig. (2017) Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals. PharmacoEconomics - Open 2:2, pages 97-107.
Crossref
Crossref
Ka Keat Lim, Sook Yee Yoon, Nur Aishah Mohd Taib, Fatiha Hana Shabaruddin, Maznah Dahlui, Yin Ling Woo, Meow Keong Thong, Soo Hwang Teo & Nathorn Chaiyakunapruk. (2018) Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients Compared to Routine Clinical Surveillance? The Case of an Upper Middle-Income Country in Asia. Applied Health Economics and Health Policy 16:3, pages 395-406.
Crossref
Crossref
Joseph Kwon, Sung Wook Kim, Wendy J. Ungar, Kate Tsiplova, Jason Madan & Stavros Petrou. (2017) A Systematic Review and Meta-analysis of Childhood Health Utilities. Medical Decision Making 38:3, pages 277-305.
Crossref
Crossref
Dirk Müller, Marion Danner, Kerstin Rhiem, Björn Stollenwerk, Christoph Engel, Linda Rasche, Lisa Borsi, Rita Schmutzler & Stephanie Stock. (2017) Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation. The European Journal of Health Economics 19:3, pages 341-353.
Crossref
Crossref
Robert C. Keskey, A. Scott LaJoie, Brad S. Sutton, In K. Kim, William G. Cheadle, Kelly M. McMasters & Nicolas Ajkay. (2017) Cost-effectiveness Analysis of Contralateral Prophylactic Mastectomy Compared to Unilateral Mastectomy with Routine Surveillance for Unilateral, Sporadic Breast Cancer. Annals of Surgical Oncology 24:13, pages 3903-3910.
Crossref
Crossref
Anna Selva, Ivan Solà, Yuan Zhang, Hector Pardo-Hernandez, R. Brian Haynes, Laura Martínez García, Tamara Navarro, Holger Schünemann & Pablo Alonso-Coello. (2017) Development and use of a content search strategy for retrieving studies on patients' views and preferences. Health and Quality of Life Outcomes 15:1.
Crossref
Crossref
Roberta Ara, John Brazier & Ismail Azzabi Zouraq. (2017) The Use of Health State Utility Values in Decision Models. PharmacoEconomics 35:S1, pages 77-88.
Crossref
Crossref
Ranjit Manchanda, Shreeya Patel, Antonis C. Antoniou, Ephrat Levy-Lahad, Clare Turnbull, D. Gareth Evans, John L. Hopper, Robert J. Macinnis, Usha Menon, Ian Jacobs & Rosa Legood. (2017) Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. American Journal of Obstetrics and Gynecology 217:5, pages 578.e1-578.e12.
Crossref
Crossref
Ewan Gray, Anna Donten, Nico Karssemeijer, Carla van Gils, D. Gareth Evans, Sue Astley & Katherine Payne. (2017) Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis. Value in Health 20:8, pages 1100-1109.
Crossref
Crossref
Virginie Nerich, Sopany Saing, Eva-Maria Gamper, Bernhard Holzner, Xavier Pivot, Rosalie Viney & Georg Kemmler. (2017) Critical appraisal of health-state utility values used in breast cancer-related cost–utility analyses. Breast Cancer Research and Treatment 164:3, pages 527-536.
Crossref
Crossref
Irmgard C. Schiller-Frühwirth, Beate Jahn, Marjan Arvandi & Uwe Siebert. (2017) Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review. Applied Health Economics and Health Policy 15:3, pages 333-351.
Crossref
Crossref
Yonghong Li, Andre R. Arellano, Lance A. Bare, Richard A. Bender, Charles M. Strom & James J. Devlin. (2017) A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer. Value in Health 20:4, pages 547-555.
Crossref
Crossref
Caroline S. Clarke, Rachael M. Hunter, Ian Shemilt & Victoria Serra-Sastre. (2017) Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLOS ONE 12:3, pages e0172731.
Crossref
Crossref
Kim Jeong & John Cairns. (2016) Systematic review of health state utility values for economic evaluation of colorectal cancer. Health Economics Review 6:1.
Crossref
Crossref
Ranjit Manchanda, Rosa Legood, Antonis C Antoniou, Vladimir S Gordeev & Usha Menon. (2016) Specifying the ovarian cancer risk threshold of ‘premenopausal risk-reducing salpingo-oophorectomy’ for ovarian cancer prevention: a cost-effectiveness analysis. Journal of Medical Genetics 53:9, pages 591-599.
Crossref
Crossref
D Gareth Evans, Susan Astley, Paula Stavrinos, Elaine Harkness, Louise S Donnelly, Sarah Dawe, Ian Jacob, Michelle Harvie, Jack Cuzick, Adam Brentnall, Mary Wilson, Fiona Harrison, Katherine Payne & Anthony Howell. (2016) Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Programme Grants for Applied Research 4:11, pages 1-210.
Crossref
Crossref
Quang A. Le. (2016) Structural Uncertainty of Markov Models for Advanced Breast Cancer. Medical Decision Making 36:5, pages 629-640.
Crossref
Crossref
Hazel Squires, Matt Stevenson, Emma Simpson, Rebecca Harvey & John Stevens. (2016) Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 34:7, pages 673-680.
Crossref
Crossref
Richard Neapolitan, Xia Jiang, Daniela P. Ladner & Bruce Kaplan. (2016) A Primer on Bayesian Decision Analysis With an Application to a Kidney Transplant Decision. Transplantation 100:3, pages 489-496.
Crossref
Crossref
Robert C Stein, Janet A Dunn, John MS Bartlett, Amy F Campbell, Andrea Marshall, Peter Hall, Leila Rooshenas, Adrienne Morgan, Christopher Poole, Sarah E Pinder, David A Cameron, Nigel Stallard, Jenny L Donovan, Christopher McCabe, Luke Hughes-Davies & Andreas Makris. (2016) OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment 20:10, pages 1-202.
Crossref
Crossref
Justin G. Trogdon, Donatus U. Ekwueme, Linda Chamiec-Case & Gery P. GuyJr.Jr.. (2016) Breast Cancer in Young Women. American Journal of Preventive Medicine 50:2, pages 262-269.
Crossref
Crossref
Derek S. Brown, Justin G. Trogdon, Donatus U. Ekwueme, Linda Chamiec-Case, Gery P. GuyJr.Jr., Florence K. Tangka, Chunyu Li, Katrina F. Trivers & Juan L. Rodriguez. (2016) Health State Utility Impact of Breast Cancer in U.S. Women Aged 18–44 Years. American Journal of Preventive Medicine 50:2, pages 255-261.
Crossref
Crossref
Christopher J Sampson, Jonathan C Tosh, Christopher P Cheyne, Deborah Broadbent & Marilyn James. (2015) Health state utility values for diabetic retinopathy: protocol for a systematic review and meta-analysis. Systematic Reviews 4:1.
Crossref
Crossref
Tessa Peasgood & John Brazier. (2015) Is Meta-Analysis for Utility Values Appropriate Given the Potential Impact Different Elicitation Methods Have on Values?. PharmacoEconomics 33:11, pages 1101-1105.
Crossref
Crossref
J. Jaime Caro, Jörgen Möller, Jonathan Karnon, James Stahl & Jack Ishak. 2015. Discrete Event Simulation for Health Technology Assessment. Discrete Event Simulation for Health Technology Assessment
256
273
.
Lukas J.A. Stalpers, Patty J. Nelemans, Sandra M.E. Geurts, Erik Jansen, Peter de Boer & André L.M. Verbeek. (2015) The indication area of a diagnostic test. Part II—the impact of test dependence, physician's decision strategy, and patient's utility. Journal of Clinical Epidemiology 68:10, pages 1129-1137.
Crossref
Crossref
Michelle Kip, Helma Monteban & Lotte Steuten. (2015)
Long-term cost–effectiveness of Oncotype DX
®
versus current clinical practice from a Dutch cost perspective
. Journal of Comparative Effectiveness Research 4:5, pages 433-445.
Crossref
Crossref
Gregory Katz, Olivier Romano, Cyril Foa, Anne-Lise Vataire, Jean-Victor Chantelard, Robert Hervé, Hugues Barletta, Axel Durieux, Jean-Pierre Martin & Rémy Salmon. (2015) Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France. PLOS ONE 10:6, pages e0128880.
Crossref
Crossref
Karen E. Bremner. (2015) Discussion and Challenges in the Use and Interpretation of Utility Assessment. International Journal of Radiation Oncology*Biology*Physics 91:2, pages 258-260.
Crossref
Crossref
Patricia R. Blank, Martin Filipits, Peter Dubsky, Florian Gutzwiller, Michael P. Lux, Jan C. Brase, Karsten E. Weber, Margaretha Rudas, Richard Greil, Sibylle Loibl, Thomas D. Szucs, Ralf Kronenwett, Matthias Schwenkglenks & Michael Gnant. (2014) Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. PharmacoEconomics 33:2, pages 179-190.
Crossref
Crossref
Ranjit Manchanda, Rosa Legood, Matthew Burnell, Alistair McGuire, Maria Raikou, Kelly Loggenberg, Jane Wardle, Saskia Sanderson, Sue Gessler, Lucy Side, Nyala Balogun, Rakshit Desai, Ajith Kumar, Huw Dorkins, Yvonne Wallis, Cyril Chapman, Rohan Taylor, Chris Jacobs, Ian Tomlinson, Uziel Beller, Usha Menon & Ian Jacobs. (2015) Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History–Based Testing. JNCI: Journal of the National Cancer Institute 107:1.
Crossref
Crossref
Taryn Bessen, Dorothy M.K. Keefe & Jonathan Karnon. (2015) DOES ONE SIZE FIT ALL? COST UTILITY ANALYSES OF ALTERNATIVE MAMMOGRAPHIC FOLLOW-UP SCHEDULES, BY RISK OF RECURRENCE. International Journal of Technology Assessment in Health Care 31:5, pages 281-288.
Crossref
Crossref
Jennifer Roberts, Pamela Lenton, Anju D Keetharuth & John Brazier. (2014) Quality of life impact of mental health conditions in England: results from the adult psychiatric morbidity surveys. Health and Quality of Life Outcomes 12:1.
Crossref
Crossref
Taryn Bessen & Jonathan Karnon. (2014) A Patient-Level Calibration Framework for Evaluating Surveillance Strategies: A Case Study of Mammographic Follow-Up After Early Breast Cancer. Value in Health 17:6, pages 669-678.
Crossref
Crossref
Sandjar DjalalovLinda RabeneckGeorge TomlinsonKaren E. BremnerRobert HilsdenJeffrey S. Hoch. (2014) A Review and Meta-analysis of Colorectal Cancer Utilities. Medical Decision Making 34:6, pages 809-818.
Crossref
Crossref
Neill Booth, Pekka Rissanen, Teuvo L.J. Tammela, Liisa Määttänen, Kimmo Taari & Anssi Auvinen. (2014) Health-Related Quality of Life in the Finnish Trial of Screening for Prostate Cancer. European Urology 65:1, pages 39-47.
Crossref
Crossref
Kouta Ito, Elena Elkin, Victoria Blinder, Nancy Keating & Niteesh Choudhry. (2013) Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer. Cancer 119:13, pages 2494-2502.
Crossref
Crossref
S Holt, G Bertelli, I Humphreys, W Valentine, S Durrani, D Pudney, M Rolles, M Moe, S Khawaja, Y Sharaiha, E Brinkworth, S Whelan, S Jones, H Bennett & C J Phillips. (2013) A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK. British Journal of Cancer 108:11, pages 2250-2258.
Crossref
Crossref
Roman Rouzier, Paolo Pronzato, Elisabeth Chéreau, Josh Carlson, Barnaby Hunt & William J. Valentine. (2013) Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Research and Treatment 139:3, pages 621-637.
Crossref
Crossref
Gerardus W.J. Frederix, Nuz Quadri, Anke M. Hövels, Fleur T. van de Wetering, Hans Tamminga, Jan H.M. Schellens & Andrew J. Lloyd. (2013) Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden. Clinical Therapeutics 35:4, pages e1-e7.
Crossref
Crossref
Gerardus W.J. Frederix, Nuz Quadri, Anke M. Hovels, Fleur T. van de Wetering, Hans Tamminga, Jan H.M. Schellens & Andrew J. Lloyd. (2012) WITHDRAWN: Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden. Health Outcomes Research in Medicine.
Crossref
Crossref
Elizabeth S. Burnside, Jagpreet Chhatwal & Oguzhan Alagoz. (2012) What Is the Optimal Threshold at Which to Recommend Breast Biopsy?. PLoS ONE 7:11, pages e48820.
Crossref
Crossref
Paul Dolan, Henry Lee & Tessa Peasgood. (2012) Losing Sight of the Wood for the Trees. PharmacoEconomics 30:11, pages 1035-1049.
Crossref
Crossref
Anne-Lise Vataire, Enora Laas, Samuel Aballéa, Joseph Gligorov, Roman Rouzier & Élisabeth Chéreau. (2012) Analyse coût-efficacité d’un test prédictif de la chimiothérapie dans le cancer du sein (Oncotype DX®) en France. Bulletin du Cancer 99:10, pages 907-914.
Crossref
Crossref
Pedro Saramago, Andrea Manca & Alex J. Sutton. (2012) Deriving Input Parameters for Cost-Effectiveness Modeling: Taxonomy of Data Types and Approaches to Their Statistical Synthesis. Value in Health 15:5, pages 639-649.
Crossref
Crossref
Sonya J. Snedecor, John A. Carter, Satyin Kaura & Marc F. Botteman. (2012) Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer. Clinical Therapeutics 34:6, pages 1334-1349.
Crossref
Crossref